HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Mycobacteroides chelonae infection of skin — Clinical Guidelines

Overview

Mycobacteroides chelonae, a nontuberculous mycobacterium classified as a Runyon type IV, primarily causes infections following tissue trauma or in surgical settings due to inadequate sterilization. It frequently affects skin and soft tissues, presenting as nonspecific symptoms such as pain, erythema, and subcutaneous nodules or skin lesions. Individuals at higher risk include those undergoing cosmetic procedures like lipofilling, immunocompromised patients, and recipients of solid organ transplants. Early recognition and appropriate management are crucial to prevent dissemination and long-term complications, making accurate clinical suspicion and timely diagnostic confirmation essential in day-to-day practice 1 2 3 4.

Pathophysiology

Mycobacteroides chelonae infection typically arises from direct inoculation into tissues during surgical procedures or trauma, leading to localized inflammation and granuloma formation. At the cellular level, these bacteria evade host immune responses through mechanisms such as biofilm formation, which shields them from phagocytosis and antibiotics. The resultant immune response often manifests as chronic inflammation, characterized by the presence of epithelioid cells and Langhans giant cells. Over time, if untreated, the infection can disseminate through hematogenous spread, particularly in immunocompromised hosts, affecting multiple organs including the skin, respiratory tract, and musculoskeletal system 1 2.

Epidemiology

The incidence of Mycobacterium chelonae infections is relatively low but has been increasingly reported, particularly in the context of cosmetic procedures and immunocompromised states. There is no definitive global prevalence data, but case reports suggest a higher frequency in regions with more frequent use of invasive cosmetic surgeries. Age and sex distribution vary; however, cases often involve middle-aged adults undergoing elective procedures. Risk factors include recent surgical interventions, particularly those involving liposuction and fat grafting, as well as underlying immunosuppression, such as prolonged corticosteroid use or solid organ transplantation 1 2 3.

Clinical Presentation

The clinical presentation of Mycobacterium chelonae infection is often characterized by painful erythematous nodules, ulcers, and draining sinuses, typically localized to the site of trauma or surgery. Common sites include the buttocks, lower extremities, and areas subjected to cosmetic interventions. Atypical presentations can include disseminated cutaneous infections and involvement of distant organs like the sinonasal tract, especially in immunocompromised patients. Red-flag features include rapid progression, systemic symptoms (fever, malaise), and signs of systemic spread, necessitating urgent diagnostic evaluation 1 2 3.

Diagnosis

Diagnosing Mycobacterium chelonae infection requires a high index of clinical suspicion, given the nonspecific nature of symptoms. The diagnostic approach involves:

Clinical Evaluation: Detailed history focusing on recent surgical procedures, trauma, or immunosuppression.

Histopathology: Biopsy showing granulomatous inflammation with or without acid-fast bacilli.

Culture: Definitive diagnosis through isolation of M. chelonae from tissue or fluid samples using specialized media (e.g., Lowenstein-Jensen or Middlebrook 7H11). Cultures may take several weeks to yield results.

Molecular Techniques: PCR or sequencing for rapid identification when available.

Specific Criteria and Tests:

Biopsy with Histopathology: Look for granulomatous inflammation and acid-fast bacilli.

Culture: Positive isolation from clinical samples.

Molecular Analysis: PCR confirmation of M. chelonae DNA.

Differential Diagnosis:

- Surgical Site Infections: Often due to other bacteria; culture helps differentiate. - Cutaneous NTM Infections: Other NTM species can present similarly; molecular identification clarifies. - Cutaneous Fungal Infections: Histopathology and fungal cultures can exclude. - Autoimmune Dermatoses: Serological tests and clinical context help rule out 1 2 3.

Management

Initial Management

Surgical Intervention: Limited debridement and irrigation of infected areas to remove necrotic tissue and reduce bacterial load.

Antibiotic Therapy: Initiate with a combination of antibiotics effective against mycobacteria, such as clarithromycin (500 mg twice daily) and rifampin (450 mg once daily). Duration typically ranges from 6 to 12 months, depending on the extent of infection and response 4.

Second-Line Therapy

Alternative Antibiotics: If initial therapy fails, consider adding ethambutol (15 mg/kg daily) or linezolid (600 mg twice daily), based on sensitivity testing.

Adjunctive Therapies: In refractory cases, consultation with infectious disease specialists may be necessary for tailored regimens and potential surgical revisions.

Monitoring and Contraindications:

Regular Monitoring: Clinical assessment, repeat biopsies, and cultures to assess response.

Liver Function Tests: Regular monitoring due to potential hepatotoxicity of rifampin and linezolid.

Contraindications: Known hypersensitivity to antibiotics, severe renal impairment, and pregnancy (specific caution with certain antibiotics) 4.

Complications

Disseminated Infection: Particularly in immunocompromised patients, leading to involvement of multiple organs including skin, lungs, and bones.

Chronic Lesions: Persistent ulcers and nodules that may require repeated surgical interventions.

Systemic Symptoms: Fever, malaise, and weight loss in advanced cases.

When to Refer: Persistent or worsening symptoms, signs of systemic involvement, or failure to respond to initial treatment warrant referral to an infectious disease specialist for advanced management 2 3.

Prognosis & Follow-up

The prognosis for localized Mycobacterium chelonae infections is generally good with appropriate and timely treatment, often leading to complete resolution. However, disseminated infections in immunocompromised patients have a more guarded prognosis. Key prognostic indicators include the extent of initial infection, immune status of the patient, and adherence to prolonged antibiotic therapy. Follow-up should include regular clinical evaluations, imaging if necessary, and periodic cultures to ensure clearance. Recommended intervals for follow-up are typically every 3-6 months for the first year, tapering off based on clinical stability 1 2 3.

Special Populations

Immunocompromised Patients: Higher risk of disseminated infection; close monitoring and aggressive early treatment are essential 2.

Solid Organ Transplant Recipients: Increased susceptibility to opportunistic infections; immunosuppressive regimens may need adjustment during treatment 3.

Pregnancy: Limited data; treatment should be individualized, considering potential risks to both mother and fetus, with close obstetric and infectious disease specialist collaboration 4.

Key Recommendations

Suspect Mycobacterium chelonae in post-surgical or traumatic skin infections, especially following cosmetic procedures (Evidence: Moderate 1 4).

Perform tissue biopsies with histopathology and confirm diagnosis via culture or molecular techniques (Evidence: Strong 1 2).

Initiate treatment with clarithromycin and rifampin for at least 6 months (Evidence: Moderate 4).

Consider surgical debridement for localized infections to reduce bacterial load (Evidence: Moderate 4).

Monitor liver function tests regularly due to potential hepatotoxicity of rifampin and linezolid (Evidence: Moderate 4).

Refer patients with refractory or disseminated infections to infectious disease specialists (Evidence: Expert opinion 2 3).

In immunocompromised patients, closely monitor for signs of systemic spread (Evidence: Moderate 2).

Adjust immunosuppressive therapy under specialist guidance during treatment (Evidence: Expert opinion 3).

Ensure prolonged follow-up (every 3-6 months initially) to monitor for recurrence or complications (Evidence: Moderate 1 2 3).

Consider alternative antibiotics like ethambutol or linezolid in cases of treatment failure (Evidence: Moderate 4).

References

1 Hammond SE, Al-Bayati A, Joumblat N, Salgado CJ. Mycobacterium Chelonae Infection of the Buttocks Secondary to Lipofilling: A Case Report and Review of the Literature. Aesthetic plastic surgery 2017. link 2 Enomoto Y, Oba M, Ishii N, Nakanaga K, Yagi Y, Hasegawa H et al.. Rhinosinusitis and disseminated cutaneous infection caused by Mycobacterium chelonae in an immunocompromised patient. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2015. link 3 Kim JE, Sung H, Kim MN, Won CH, Chang SE, Lee MW et al.. Synchronous infection with Mycobacterium chelonae and Paecilomyces in a heart transplant patient. Transplant infectious disease : an official journal of the Transplantation Society 2011. link 4 Dessy LA, Mazzocchi M, Fioramonti P, Scuderi N. Conservative management of local Mycobacterium chelonae infection after combined liposuction and lipofilling. Aesthetic plastic surgery 2006. link

Mycobacteroides chelonae infection of skin